Jenny Rooke, founder of Genoa Ventures, invests in early-stage life sciences companies (pre-seed to Series A). See portfolio, sector focus and contact routes.
Jenny Rooke, founder of Genoa Ventures, invests in early-stage life sciences companies (pre-seed to Series A) at the intersection of biology, technology, and data science, with first checks of $1–$2 million for seed and $2–$5 million for Series A. Her portfolio includes notable companies such as Zymergen, Caribou Biosciences, IonPath, and emerging diagnostics firms like InterVenn and Aqtual, reflecting a focus on research tools, molecular diagnostics, synthetic biology, and ag biotech. Rooke’s distinctive thesis centers on “bioconvergence” and the belief that precision medicine requires *informed medicine*—integrating multimodal molecular and physiological data to guide clinical decisions, rather than relying on single-answer diagnostics.
This profile is part of the StartupFundraising investor database: focus, portfolio history, disclosed location and contact routes, refreshed as new filings and rounds are ingested. Founders use it to check fit before reaching out and to find investors in San Francisco.
Investors like Jenny Rooke · Full investor directory · Investor access · Company funding database